At a glance
- Originator Nippon Organon
- Class Antihyperglycaemics; Antirheumatics; Hydroxamic acids; Small molecules
- Mechanism of Action Matrix metalloproteinase 1 inhibitors; Matrix metalloproteinase 3 inhibitors; Matrix metalloproteinase 9 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Graft-versus-host disease; Type 2 diabetes mellitus